FDA puts Cadence pain drug app on hold

The FDA has put Cadence Pharma's application to market its pain and fever therapy on hold. The agency alerted Cadence that it couldn't approve the drug--to be marketed as Ofirmev--until manufacturing problems at a third-party facility were resolved. Cadence emphasized that the FDA did not ask for any new studies. Cadence release | Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.